These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10690702)

  • 21. Seropositive myasthenia gravis: a nationwide epidemiologic study.
    Heldal AT; Owe JF; Gilhus NE; Romi F
    Neurology; 2009 Jul; 73(2):150-1. PubMed ID: 19597135
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antibodies to acetylcholine receptor. Diagnosis and therapeutic interest in myasthenia gravis (author's transl)].
    de Crousaz G
    Ann Chir; 1980 Mar; 34(3):188-92. PubMed ID: 7369693
    [No Abstract]   [Full Text] [Related]  

  • 23. Diagnostic sensitivity of the laboratory tests in myasthenia gravis.
    Oh SJ; Kim DE; Kuruoglu R; Bradley RJ; Dwyer D
    Muscle Nerve; 1992 Jun; 15(6):720-4. PubMed ID: 1324429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
    Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
    Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.
    Evoli A; Alboini PE; Damato V; Iorio R
    Neurology; 2016 Mar; 86(11):1070-1. PubMed ID: 26873957
    [No Abstract]   [Full Text] [Related]  

  • 26. Single fiber EMG as a prognostic tool in myasthenia gravis.
    Baruca M; Leonardis L; Podnar S; Hojs-Fabjan T; Grad A; Jerin A; Blagus R; Šega-Jazbec S
    Muscle Nerve; 2016 Dec; 54(6):1034-1040. PubMed ID: 27144873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.
    Niks EH; Kuks JB; Verschuuren JJ
    J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):417-8. PubMed ID: 17056627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent falls as onset of myasthenia gravis in elderly adults.
    Hernandez Ocampo EM; Aragonès Pascual JM
    J Am Geriatr Soc; 2012 Dec; 60(12):2379. PubMed ID: 23231565
    [No Abstract]   [Full Text] [Related]  

  • 29. The laboratory diagnosis of mild myasthenia gravis.
    Kelly JJ; Daube JR; Lennon VA; Howard FM; Younge BR
    Ann Neurol; 1982 Sep; 12(3):238-42. PubMed ID: 7137958
    [No Abstract]   [Full Text] [Related]  

  • 30. Diagnostic use of autoantibodies in myasthenia gravis.
    Leite MI; Waters P; Vincent A
    Autoimmunity; 2010 Aug; 43(5-6):371-9. PubMed ID: 20380582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-acetylcholine receptor antibody].
    Ohta M; Ohta K
    Nihon Rinsho; 1999 Nov; 57 Suppl():509-13. PubMed ID: 10635897
    [No Abstract]   [Full Text] [Related]  

  • 32. [D-penicillamine-induced myasthenia gravis].
    Frey RA; Keller F; Michel BA
    Schweiz Med Wochenschr; 1994 May; 124(20):852-6. PubMed ID: 8209208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myasthenia gravis (2). Antibodies against acetylcholinergic receptros in myasthenia gravis].
    Bergström K; Lefvert AK
    Lakartidningen; 1978 Oct; 75(41):3665-7. PubMed ID: 692232
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
    Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
    JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.
    Punga AR; Flink R; Askmark H; Stålberg EV
    Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune myasthenia gravis.
    Jayawant S; Parr J; Vincent A
    Handb Clin Neurol; 2013; 113():1465-8. PubMed ID: 23622368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Myasthenia gravis (1). Experimental myasthenia gravis--a tool for the study of the pathogenesis, diagnosis and treatment of myasthenia gravis].
    Heilbronn E
    Lakartidningen; 1978 Oct; 75(41):3663-4, 3669. PubMed ID: 692231
    [No Abstract]   [Full Text] [Related]  

  • 39. Facial and bulbar muscle atrophy in acetylcholine receptor antibody-positive myasthenia gravis.
    Grativvol RS; Silva AM; Guedes BF; Estephan EP; Mendonça RH; Zambon AA; Heise CO; Zanoteli E
    Arq Neuropsiquiatr; 2017 Mar; 75(3):197-198. PubMed ID: 28355331
    [No Abstract]   [Full Text] [Related]  

  • 40. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.